Literature DB >> 30604378

Serum Procalcitonin as a Potential Early Predictor of Short-Term Outcomes in Acute Severe Ulcerative Colitis.

Hui-Min Wu1, Juan Wei2, Jin Li3, Kai Wang4, Lei Ye1, Ying Qi1, Bo-Si Yuan1, Yu-Lin Yang1, Li Zhao3, Zhao Yang1, Miao-Fang Yang1, Jian-Feng Gong4, Fang-Yu Wang5,6.   

Abstract

BACKGROUND: Delayed colectomy can be life-threatening for patients with acute severe ulcerative colitis (ASUC). However, few biomarkers can predict the outcomes of ASUC patients before treatment. Serum procalcitonin (PCT) has been observed to be increased in ASUC patients. AIM: The aim of this study was to estimate the association between serum PCT and short-term outcomes in patients with ASUC.
METHODS: A single-center observational study was conducted at a referral hospital from January 2012 to January 2018. Hospitalized ASUC patients, who were administered intravenous corticosteroids (IVCS), were enrolled and followed up for 6 months. The primary outcome was IVCS failure; the secondary outcome was colectomy. Relationships between indicators and clinical outcomes were assessed.
RESULTS: Of 152 ASUC patients enrolled in this study, 81 responded to IVCS and 71 failed (62 required short-term colectomy and 9 responded to second-line rescue therapy). Serum PCT on admission was significantly higher in IVCS-failure cases and surgical cases than in medical responders. Serum PCT ≥ 0.10 µg/L (OR = 4.134, p = 0.001) predicted IVCS failure with specificity of 0.741, and the combined measurement with fecal calprotectin (FC) ≥ 1500 µg/g improved the sensitivity. Serum PCT correlated significantly with the Ulcerative Colitis Endoscopic Index of Severity (r = 0.416, p < 0.001) and FC (r = 0.384, p < 0.001).
CONCLUSION: Serum PCT on admission could be a potential early non-invasive predictive biomarker for IVCS failure in ASUC patients, and a combination of PCT and FC could improve the predictive value.

Entities:  

Keywords:  Acute severe ulcerative colitis (ASUC); Biomarker; Colectomy; Intravenous corticosteroids (IVCS); Outcomes; Procalcitonin (PCT)

Year:  2019        PMID: 30604378     DOI: 10.1007/s10620-018-5446-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  32 in total

Review 1.  The pattern and outcome of acute severe colitis.

Authors:  Lotte C Dinesen; Alissa J Walsh; Marijana Nedeljkovic Protic; Graham Heap; Fraser Cummings; Bryan F Warren; Bruce George; Neil J M Mortensen; Simon P L Travis
Journal:  J Crohns Colitis       Date:  2010-02-19       Impact factor: 9.071

2.  Reliability and initial validation of the ulcerative colitis endoscopic index of severity.

Authors:  Simon P L Travis; Dan Schnell; Piotr Krzeski; Maria T Abreu; Douglas G Altman; Jean-Frédéric Colombel; Brian G Feagan; Stephen B Hanauer; Gary R Lichtenstein; Philippe R Marteau; Walter Reinisch; Bruce E Sands; Bruce R Yacyshyn; Patrick Schnell; Christian A Bernhardt; Jean-Yves Mary; William J Sandborn
Journal:  Gastroenterology       Date:  2013-07-25       Impact factor: 22.682

3.  Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis.

Authors:  Han Ho Jeon; Hyun Jung Lee; Hui Won Jang; Jin Young Yoon; Yoon Suk Jung; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

Review 4.  Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression.

Authors:  Dan Turner; Catharine M Walsh; A Hillary Steinhart; Anne M Griffiths
Journal:  Clin Gastroenterol Hepatol       Date:  2006-12-04       Impact factor: 11.382

5.  Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization.

Authors:  R H Snider; E S Nylen; K L Becker
Journal:  J Investig Med       Date:  1997-12       Impact factor: 2.895

6.  Predicting outcome in severe ulcerative colitis.

Authors:  S P Travis; J M Farrant; C Ricketts; D J Nolan; N M Mortensen; M G Kettlewell; D P Jewell
Journal:  Gut       Date:  1996-06       Impact factor: 23.059

Review 7.  Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis.

Authors:  Christina Wacker; Anna Prkno; Frank M Brunkhorst; Peter Schlattmann
Journal:  Lancet Infect Dis       Date:  2013-02-01       Impact factor: 25.071

8.  Procalcitonin increase after endotoxin injection in normal subjects.

Authors:  P Dandona; D Nix; M F Wilson; A Aljada; J Love; M Assicot; C Bohuon
Journal:  J Clin Endocrinol Metab       Date:  1994-12       Impact factor: 5.958

9.  Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications.

Authors:  J Randall; B Singh; B F Warren; S P L Travis; N J Mortensen; B D George
Journal:  Br J Surg       Date:  2010-03       Impact factor: 6.939

10.  Sepsis Markers Soluble IL-2 Receptor and Soluble CD14 Subtype as Potential Biomarkers for Complete Mucosal Healing in Patients With Inflammatory Bowel Disease.

Authors:  Shuhei Hosomi; Hirokazu Yamagami; Shigehiro Itani; Tomomi Yukawa; Koji Otani; Yasuaki Nagami; Fumio Tanaka; Koichi Taira; Noriko Kamata; Tetsuya Tanigawa; Masatsugu Shiba; Toshio Watanabe; Yasuhiro Fujiwara
Journal:  J Crohns Colitis       Date:  2018-01-05       Impact factor: 9.071

View more
  3 in total

1.  Predictive Value of Procalcitonin in Acute Severe Ulcerative Colitis: Not Quite PerfeCT?

Authors:  Deok Whan Kim; Jeong Min An; Seong Pyo Hong; Ki Baik Hahm
Journal:  Dig Dis Sci       Date:  2019-11       Impact factor: 3.199

Review 2.  The Management of the Hospitalized Ulcerative Colitis Patient: the Medical-Surgical Conundrum.

Authors:  Michele Carvello; Joseph Watfah; Marcin Włodarczyk; Antonino Spinelli
Journal:  Curr Gastroenterol Rep       Date:  2020-02-10

Review 3.  Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions.

Authors:  Tom Holvoet; Triana Lobaton; Pieter Hindryckx
Journal:  Clin Exp Gastroenterol       Date:  2021-03-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.